| ViraferonPeg (peginterferon-α-2b) / Merck (MSD) |
2012-003389-42: Etude évaluant l’efficacité et la tolérance de l’association Sprycel® et PegIFN-α2b comme premier traitement des patients atteints de Leucémie Myéloïde Chronique en phase chronique nouvellement diagnostiquée |
|
|
| Ongoing | 2 | 70 | Europe | Tablet, Powder and solvent for solution for injection, SPRYCEL® 100mg, VIRAFERONPEG®, 50 µg | CHU DE POITIERS, CHU DE POITIERS | Patients with newly diagnosed chronic phase Chronic Myeloid Leukemia (CP-CML), not previously treated with Tyrosine Kinase Inhibitors (TKIs). First line therapy., Patients with newly diagnosed chronic phase Chronic Myeloid Leukemia (CP-CML), not previously treated with Tyrosine Kinase Inhibitors (TKIs). First line therapy., Diseases [C] - Blood and lymphatic diseases [C15] | | | | |
NCT00539591: Phase II Study Incorporating Pegylated Interferon In the Treatment For Children With High-Risk Melanoma |
|
|
| Active, not recruiting | 2 | 29 | US | Peginterferon alfa-2b, PEG-Intron(R), pegylated interferon alfa-2b, Temozolomide, Temodar(R), SCH 52365, Recombinant interferon alfa-2b, Intron®, non-pegylated interferon alfa-2b | St. Jude Children's Research Hospital, Schering-Plough | Malignant Melanoma | 06/15 | 05/26 | | |
2012-005466-34: Therapeutic Vaccination against HPV16 in HIV+ Men with anal dysplasia Therapeutische vaccinatie tegen HPV16 bij HIV-positieve mannen met anale dysplasie |
|
|
| Ongoing | 2 | 45 | Europe | SLP-HPV-01®, Pegintron, Pegintron, Pegintron | Academic Medical Center, The Netherlands Organisation for Health Research and Development | HPV16-induced intra-anal high-grade AIN (grade 2-3) in HIV+ men, that was resistant to, or recurred after conventional cauterization or other forms of local treatment. | | | | |
2005-002636-97: An open-label, phase II study of matured dendritic cells pulsed ex vivo with 3 melanoma cell line lysates (IDD-3) with or without peginterferon alpha-2b (PegIFN-a 2b) in patients with resected stage II or III melanoma |
|
|
| Ongoing | 2 | 20 | Europe | UVIDEM, peginterferon alfa-2b, IDD-3, PegIntron 150 micrograms powder and solvent for solution for injection in pre-filled pen, PegIntron 150 micrograms powder and solvent for solution for injection in pre-filled pen | Immuno-Designed Molecules | Patient with a histologically confirmed stage IIc, IIIb or IIIc primary cutaneous melanoma or unknown primary (AJCC staging). | | | | |
2008-004611-35: Phase I/II study: on the toxicity and effects of combining the p53 synthetic long peptides vaccine with either Imiquimod or Interferon-alfa to induce polarized p53-specific immunity in patients treated for colorectal cancer |
|
|
| Ongoing | 2 | 20 | Europe | p53-SLP vaccine, Aldara, PEGintron, Aldara, PEGintron | Leiden University Medical Center | adult both male and femal patients treated for colorectal cancer | | | | |
2013-003295-12: Kombinationsbehandling med Interferon og JAK1-2 Hæmmer i behandlingen af Ph-Negativ Myeloprolifertiv Cancer |
|
|
| Ongoing | 2 | 50 | Europe | Jakavi, Jakavi, Pegasys 135 microgram, PegIntron 50 microgram, Jakavi, Pegasys 135 microgram, PegIntron 50 microgram | Roskilde University Hospital, Novartis | Polycythemia vera Hyperproliferativ myelofibrosis, Diseases [C] - Blood and lymphatic diseases [C15] | | | | |
NCT00678951: Pegintron to Treat Plexiform Neurofibromas in Children and Young Adults |
|
|
| Recruiting | 2 | 90 | US | PEG-interferon alfa-2b, MRI | National Cancer Institute (NCI) | Neurofibromatosis Type 1, Plexiform Neurofibroma | 01/16 | 01/16 | | |
2021-002361-17: Study aimed at evaluating the efficacy of the combination of the two drugs, Venetoclax and Azacitidine, on the treatment of patients suffering from Acute Myeloid Leukemia with NPM1 mutation. Studio volro a valutare l'efficacia della combinazione dei due farmaci, Venetoclax ed Azacitidina, sul trattamento di pazienti affetti da Leucemia Mieloide Acuta con mutazione di NPM1. |
|
|
| Not yet recruiting | 2 | 35 | Europe | Azacitidina, Venclyxto 100 mg compresse rivestite con film, [NA], Powder for suspension for injection, Film-coated tablet, PEGINTRON - 100 MCG POLVERE E SOLVENTE PER SOLUZIONE INIETTABILE IN CARTUCCE A DUE SCOMPARTI IN 4 PENNE PRERIEMPITE + 4 AGHI + 8 TAMPONI USO SOTTOCUTANEO | FONDAZIONE GIMEMA (GRUPPO ITALIANO MALATTIE EMATOLOGICHE DELL' ADULTO) FRANCO MANDELLI ONLUS, ABBVIE S.r.l., Fondazione GIMEMA Franco Mandelli Onlus | Acute Myeloid Leukemia with NPM1 mutation. Leucemia Mieloide Acuta con mutazione NPM1., Disease that develops in the bone marrow and progresses quickly. If immature cells in the marrow, the corpuscular part of the blood, undergo mutations and become adults, AML is born. Malattia che si sviluppa nel midollo osseo e progredisce velocemente. Se le cellule immature nel midollo, la parte corpuscolata del sangue, subiscono mutazioni diventando adulte, si origina la LMA., Diseases [C] - Blood and lymphatic diseases [C15] | | | | |
